Skip to main content
. 2016 May 13;7(25):37868–37881. doi: 10.18632/oncotarget.9350

Figure 7. Enzalutamide treatment promotes invasion and migration of prostate cancer cells and DANCR knockdown decreased the promotion.

Figure 7

(A) Enzalutamide treatment increases the expression of DANCR in C4-2B and CW22RV1 cells, as detected by RT-qPCR assay. (B) Knockdown of DANCR decreases the cell invasion ability enhanced by enzalutamide in C4-2B and CW22RV1 cells, as detected by transwell assay. (C, D) Knockdown of DANCR increases expression of TIMP2/3 inhibited by enzalutamide in C4-2B and CW22RV1 cells, as detected by RT-qPCR assay and western blot analysis. *p < 0.05, **p < 0.01, ***p < 0.001.